Found 32 Enz. Inhib. hit(s) with all data for entry = 8274 TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.80nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2.10nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3.10nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 8.5nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 120nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 210nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 354nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 356nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 371nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 385nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 414nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 432nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 447nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 451nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 473nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 531nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 587nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 724nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 748nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 779nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 882nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 930nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [2-188]/Protein Mdm4 [2-185](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.45E+3nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [2-188]/Protein Mdm4 [2-185](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.51E+3nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.67E+3nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [2-188]/Protein Mdm4 [2-185](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2.13E+3nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2.91E+3nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3.11E+3nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [18-26]/E3 ubiquitin-protein ligase Mdm2 [2-188](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 4.30E+3nMT: 2°CAssay Description:Assay 2: For selected compounds displaying IC50s between 0.05 and 5 nM on MDM2, a slightly modified assay is used with the following adaptations: 0.1...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [2-188]/Protein Mdm4 [2-185](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.40E+4nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [2-188]/Protein Mdm4 [2-185](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.67E+4nMT: 2°CAssay Description:Assay 1: This assay was used to evaluate compounds displaying inhibition of p53-MDM2 interaction and p53-MDM4 interaction at IC50s of 0.005 to 50 &mu...More data for this Ligand-Target Pair
